ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 597,52
-0,23%
Dow Jones
42 063,36
0,09%
DAX
18 720,01
-1,47%
Brent Oil
74,135
0,00%
Bitcoin
63 293,59
-0,13%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. C4 Therapeutics Inc (CCCC)

  7. C4 Therapeutics Inc (CCCC) Actualités

CCCC

C4 Therapeutics (CCCC)

C4 Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:CCCC
DateHeureSourceTitreSymboleSociété
20/09/202422h13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CCCCC4 Therapeutics Inc
13/09/202416h00GlobeNewswire Inc.C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024NASDAQ:CCCCC4 Therapeutics Inc
10/09/202413h00GlobeNewswire Inc.C4 Therapeutics Announces Delivery of Second Development Candidate to BiogenNASDAQ:CCCCC4 Therapeutics Inc
09/09/202400h05GlobeNewswire Inc.C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024NASDAQ:CCCCC4 Therapeutics Inc
03/09/202422h51Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CCCCC4 Therapeutics Inc
03/09/202413h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CCCCC4 Therapeutics Inc
03/09/202413h00GlobeNewswire Inc.C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of DirectorsNASDAQ:CCCCC4 Therapeutics Inc
29/08/202413h00GlobeNewswire Inc.C4 Therapeutics to Participate in Upcoming September Investor ConferencesNASDAQ:CCCCC4 Therapeutics Inc
14/08/202413h00GlobeNewswire Inc.C4 Therapeutics Announces European Society for Medical Oncology (ESMO) Changed the Previously Accepted CFT1946 Preliminary Phase 1 Abstract to a Proffered Paper PresentationNASDAQ:CCCCC4 Therapeutics Inc
01/08/202413h27Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CCCCC4 Therapeutics Inc
01/08/202413h00GlobeNewswire Inc.C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:CCCCC4 Therapeutics Inc
16/07/202422h01GlobeNewswire Inc.C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024NASDAQ:CCCCC4 Therapeutics Inc
08/07/202413h00GlobeNewswire Inc.C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation DayNASDAQ:CCCCC4 Therapeutics Inc
10/06/202413h00GlobeNewswire Inc.C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of DirectorsNASDAQ:CCCCC4 Therapeutics Inc
08/05/202413h00GlobeNewswire Inc.C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:CCCCC4 Therapeutics Inc
29/04/202422h01GlobeNewswire Inc.C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:CCCCC4 Therapeutics Inc
09/04/202413h00GlobeNewswire Inc.C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology ForumNASDAQ:CCCCC4 Therapeutics Inc
08/04/202414h00GlobeNewswire Inc.C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024NASDAQ:CCCCC4 Therapeutics Inc
05/03/202422h30GlobeNewswire Inc.C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024NASDAQ:CCCCC4 Therapeutics Inc
04/03/202413h00GlobeNewswire Inc.C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic ProteinsNASDAQ:CCCCC4 Therapeutics Inc
22/02/202415h01Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:CCCCC4 Therapeutics Inc
22/02/202413h20Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:CCCCC4 Therapeutics Inc
22/02/202413h00GlobeNewswire Inc.C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business HighlightsNASDAQ:CCCCC4 Therapeutics Inc
14/02/202415h21Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CCCCC4 Therapeutics Inc
05/02/202416h24Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:CCCCC4 Therapeutics Inc
09/01/202422h01GlobeNewswire Inc.C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation MedicinesNASDAQ:CCCCC4 Therapeutics Inc
04/01/202422h01GlobeNewswire Inc.C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta PharmaceuticalsNASDAQ:CCCCC4 Therapeutics Inc
04/01/202413h00GlobeNewswire Inc.C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:CCCCC4 Therapeutics Inc
12/12/202322h01GlobeNewswire Inc.C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple MyelomaNASDAQ:CCCCC4 Therapeutics Inc
12/12/202315h15AllPennyStocks.comBiotech Catches Major Premarket BidNASDAQ:CCCCC4 Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:CCCC

Dernières Valeurs Consultées

EU
GLE
Societe Generale
NASDAQ
MSFT
Microsoft
EU
BEL20
Bel 20
EU
BNP
BNP Paribas
EU
LR
Legrand
EU
PX1
CAC 40
EU
RNO
Renault
EU
HO
Thales
EU
RI
Pernod Ricard
EU
VK
Vallourec
EU
EN
Bouygues
COIN
DOGEUSD
Dogecoin
NASDAQ
GOOGL
Alphabet
COIN
BTCUSD
Bitcoin
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés